Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Becton, Dickinson and Company

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Medical Segment Operating Income

Medical Segment Operating Income % Chg.

Medical Segment Operating Income Common Size

Life Sciences Segment Operating Income

Life Sciences Segment Operating Income % Chg.

Life Sciences Segment Operating Income Common Size

Interventional Segment Operating Income

Interventional Segment Operating Income % Chg.

Interventional Segment Operating Income Common Size

Other EBIT

Other EBIT % Chg.

Other EBIT Common Size

Total EBIT

Total EBIT Common Size

Total EBIT % Chg.

Medical Segment Operating Income (Pre-FY2025 Reporting)

Medical Segment Operating Income (Pre-FY2025 Reporting) % Chg.

Medical Segment Operating Income (Pre-FY2025 Reporting) Common Size

Life Sciences Segment Operating Income (Pre-FY2025 Reporting)

Life Sciences Segment Operating Income (Pre-FY2025 Reporting) % Chg.

Life Sciences Segment Operating Income (Pre-FY2025 Reporting) Common Size

Interventional Segment Operating Income (Pre-FY2025 Reporting)

Interventional Segment Operating Income (Pre-FY2025 Reporting) % Chg.

Interventional Segment Operating Income (Pre-FY2025 Reporting) Common Size

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

International Revenue

International Revenue % Chg.

International Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Medication Delivery Solutions Revenue

Medication Delivery Solutions Revenue % Chg.

Medication Delivery Solutions Revenue Common Size

Medication Management Solutions Revenue

Medication Management Solutions Revenue % Chg.

Medication Management Solutions Revenue Common Size

Diabetes Care Revenue

Diabetes Care Revenue % Chg.

Diabetes Care Revenue Common Size

Pharmaceutical Systems Revenue

Pharmaceutical Systems Revenue % Chg.

Pharmaceutical Systems Revenue Common Size

Advanced Patient Monitoring Revenue

Advanced Patient Monitoring Revenue % Chg.

Advanced Patient Monitoring Revenue Common Size

Specimen Management Revenue

Specimen Management Revenue % Chg.

Specimen Management Revenue Common Size

Diagnostic Solusions Revenue

Diagnostic Solusions Revenue % Chg.

Diagnostic Solusions Revenue Common Size

Integrated Diagnostic Solutions Revenue

Integrated Diagnostic Solutions Revenue % Chg.

Integrated Diagnostic Solutions Revenue Common Size

Biosciences Revenue

Biosciences Revenue % Chg.

Biosciences Revenue Common Size

Surgery Revenue

Surgery Revenue % Chg.

Surgery Revenue Common Size

Peripheral Intervention Revenue

Peripheral Intervention Revenue % Chg.

Peripheral Intervention Revenue Common Size

Urology and Critical Care Revenue

Urology and Critical Care Revenue % Chg.

Urology and Critical Care Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Medical Revenue

Medical Revenue % Chg.

Medical Revenue Common Size

Life Sciences Revenue

Life Sciences Revenue % Chg.

Life Sciences Revenue Common Size

Interventional Revenue

Interventional Revenue % Chg.

Interventional Revenue Common Size

Revenue	Sep '25	Sep '24
Medication Delivery Solutions Revenue	4,575	4,429
Medication Management Solutions Revenue	3,474	3,297
Diabetes Care Revenue	—	—
Pharmaceutical Systems Revenue	2,324	2,273
Advanced Patient Monitoring Revenue	1,082	74
Specimen Management Revenue	1,871	1,833
Diagnostic Solusions Revenue	1,838	1,846
Integrated Diagnostic Solutions Revenue	3,709	3,679
Biosciences Revenue	1,458	1,512
Surgery Revenue	1,572	1,492
Peripheral Intervention Revenue	1,996	1,933
Urology and Critical Care Revenue	1,649	1,554
Other Revenue	1	-65
Total Revenue	21,840	20,178

Revenue by Geography	Sep '25	Sep '24
United States Revenue	12,790	11,663
International Revenue	9,049	8,515
Other Revenue by Geography	1	—
Total Revenue by Geography	21,840	20,178

Revenue	Sep '25	Sep '24
Medical Revenue	11,456	10,074
Life Sciences Revenue	5,167	5,191
Interventional Revenue	5,217	4,980
Other Revenue	—	-67
Total Revenue	21,840	20,178

EBIT	Sep '25	Sep '24
Medical Segment Operating Income	4,140	3,583
Life Sciences Segment Operating Income	1,641	1,616
Interventional Segment Operating Income	2,253	2,115
Other EBIT	-5,455	-4,917
Total EBIT	2,579	2,397

EBIT	Sep '25	Sep '24
Medical Segment Operating Income (Pre-FY2025 Reporting)	—	2,742
Life Sciences Segment Operating Income (Pre-FY2025 Reporting)	—	1,595
Interventional Segment Operating Income (Pre-FY2025 Reporting)	—	1,420
Other EBIT	—	-3,360
Total EBIT	2,579	2,397